Drug Trial Radar · NCT04974398
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
296
Actual
Start
Aug 16, 2021
Primary completion
Feb 23, 2026
Study completion Dec 23, 2026
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Conditions
- Nasopharyngeal Carcinoma
Interventions
PenpulimabDrug
Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) +cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per cycle; followed by penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment.
placeboDrug
Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per cycle; followed by placebo(200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment. Subjects in Arm B will have the opportunity to crossover to openlabel treatment with penpulimab monotherapy after radiographic disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Up to 2 years
Locations
56 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Winship Cancer Institute/Emory University
Atlanta, Georgia
University of Michigan
Ann Arbor, Michigan
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
St Vincent's Public Hospital Sydney
Darlinghurst, New South Wales, Australia
Genesis Care North Shore
St Leonards, New South Wales, Australia
Sir Charles Gardner
Heidelberg, Victoria, Australia
Austin Health
Nedlands, Western Australia, Australia
Hospital de Câncer de Barretos - Fundação Pio XII
Barretos, REG1, Brazil
Grupo Oncoclínicas
Botafogo, REG1, Brazil
Hospital Bruno Born
Lajeado, REG1, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, REG1, Brazil
Centro de Estudos e Pesquisa de Hematologia
Santo André, REG1, Brazil
Instituto do Câncer do Estado de São Paulo (ICESP)
São Paulo, REG1, Brazil
Centro de Câncer A. C. Camargo
São Paulo, REG1, Brazil
Alberta Health Services (Tom Baker Cancer Centre)
Calgary, Alberta, Canada
Toronto Sunnybrook Hospital
Toronto, Ontario, Canada
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Dongguan People's Hospital
Dongguan, Guangdong, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
Guangzhou Panyu Central Hospital
Guangzhou, Guangdong, China
Jiangmen Central Hospital
Jiangmen, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.